These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38760830)

  • 1. HER3 (ERBB3) amplification in liposarcoma - a putative new therapeutic target?
    Becker AK; Puladi B; Xie K; Cassataro A; Götzl R; Hölzle F; Beier JP; Knüchel-Clarke R; Braunschweig T
    World J Surg Oncol; 2024 May; 22(1):131. PubMed ID: 38760830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical value of fluorescence
    Wang W; Li X; Liu P; Dong Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):228-233. PubMed ID: 37042132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
    Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FISH Diagnostic Assessment of
    Gambella A; Bertero L; Rondón-Lagos M; Verdun Di Cantogno L; Rangel N; Pitino C; Ricci AA; Mangherini L; Castellano I; Cassoni P
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674856
    [No Abstract]   [Full Text] [Related]  

  • 5. Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics.
    Kimura H; Dobashi Y; Nojima T; Nakamura H; Yamamoto N; Tsuchiya H; Ikeda H; Sawada-Kitamura S; Oyama T; Ooi A
    Int J Clin Exp Pathol; 2013; 6(7):1306-16. PubMed ID: 23826411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR.
    Sirvent N; Coindre JM; Maire G; Hostein I; Keslair F; Guillou L; Ranchere-Vince D; Terrier P; Pedeutour F
    Am J Surg Pathol; 2007 Oct; 31(10):1476-89. PubMed ID: 17895748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of
    Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S
    Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.
    Lee SE; Kim YJ; Kwon MJ; Choi DI; Lee J; Cho J; Seo SW; Kim SJ; Shin YK; Choi YL
    Histol Histopathol; 2014 Jan; 29(1):127-38. PubMed ID: 23852861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor.
    Kashima T; Halai D; Ye H; Hing SN; Delaney D; Pollock R; O'Donnell P; Tirabosco R; Flanagan AM
    Mod Pathol; 2012 Oct; 25(10):1384-96. PubMed ID: 22699518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
    Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
    Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
    Shimada S; Ishizawa T; Ishizawa K; Matsumura T; Hasegawa T; Hirose T
    Hum Pathol; 2006 Sep; 37(9):1123-9. PubMed ID: 16938516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of MDM2 and TP53 genes in canine liposarcoma.
    Muscatello LV; de Biase D; Maloberti T; di Oto E; Tallini G; Pellegrino V; Bacci B; Roccabianca P; Lepri E; Crippa L; Avallone G
    Sci Rep; 2024 Jun; 14(1):14087. PubMed ID: 38890407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT6 is amplified in a subset of dedifferentiated liposarcoma.
    Doyle LA; Tao D; Mariño-Enríquez A
    Mod Pathol; 2014 Sep; 27(9):1231-7. PubMed ID: 24457460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
    Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
    Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of Fédération Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases.
    Jour G; Gullet A; Liu M; Hoch BL
    Mod Pathol; 2015 Jan; 28(1):37-47. PubMed ID: 25059573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons learnt from MDM2 fluorescence in-situ hybridisation analysis of 439 mature lipomatous lesions with an emphasis on atypical lipomatous tumour/well-differentiated liposarcoma lacking cytological atypia.
    Vargas AC; Joy C; Cheah AL; Jones M; Bonar F; Brookwell R; Garrone B; Talbot J; Harraway J; Gill AJ; Maclean FM
    Histopathology; 2022 Jan; 80(2):369-380. PubMed ID: 34523152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases.
    Ricciotti RW; Baraff AJ; Jour G; Kyriss M; Wu Y; Liu Y; Li SC; Hoch B; Liu YJ
    Cancer Genet; 2017 Dec; 218-219():69-80. PubMed ID: 29153098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms.
    Weaver J; Downs-Kelly E; Goldblum JR; Turner S; Kulkarni S; Tubbs RR; Rubin BP; Skacel M
    Mod Pathol; 2008 Aug; 21(8):943-9. PubMed ID: 18500263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.
    Alaggio R; Coffin CM; Weiss SW; Bridge JA; Issakov J; Oliveira AM; Folpe AL
    Am J Surg Pathol; 2009 May; 33(5):645-58. PubMed ID: 19194281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.